Approved in combination with nivolumab for patients who progress on prior anti-PD-1 therapy
— Approved in combination with nivolumab for patients who progress on prior anti-PD-1 therapy
August 6, 2026
• 2 min read
The FDA granted accelerated approval to vusolimogene oderparepvec (Tudriqev), known as RP1, in combination with nivolumab (Opdivo) to treat adults with unresectable advanced cutaneous melanoma, the agency announced Thursday.
The genetically modified oncolytic viral therapy is indicated for patients who experienced disease progression with an anti-PD-1-based therapy.
FDA OKs accelerated approval to twice-rejected Tudriqev with Opdivo for advanced melanoma
Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections
Replimune rebounds to win FDA approval of melanoma drug
FDA approves Replimune's Tudriqev melanoma drug on third try
Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle
FDA approves Replimune melanoma drug previously rejected twice
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto - Novartis (NYSE:NVS)
FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients
FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer
The FDA has granted accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for adults with…
Vote at odds with FDA reviewers
The FDA rejected vusolimogene oderparepvec twice under former Commissioner Marty Makary, who stepped down earlier this month
Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting
Replimune wins accelerated FDA approval for RP1 in advanced melanoma after two rejections, despite data concerns. Drug combines…
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA…
